Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986460 bioavailability and dose escalation in healthy volunteers
NCT06877702Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2025
- Primary completion
- Dec 2025
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BMS-986460 (8 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Adverse Events at 43 days, Serious Adverse Events at 43 days and 11 more. Started Mar 2025; status: completed.
02
Drugs
BMS-986460
Beyond the preview
Go deeper on NCT06877702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06877702.